Management ChangeApr 29, 2026, 01:09 PM
XBIT CEO John Simard Retires; Sushma Shivaswamy Named Interim CEO
AI Summary
XBiotech Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2025, to include previously omitted information regarding Part III, Items 10 through 14. The amendment details the retirement of John Simard as President and CEO, effective December 8, 2025, and the appointment of Dr. Sushma Shivaswamy as Interim CEO and Chief Scientific Officer. It also provides comprehensive information on executive compensation, corporate governance, and board committee structures for the fiscal year 2025.
Key Highlights
- John Simard retired as President & CEO on December 8, 2025, continuing as Chairman.
- Dr. Sushma Shivaswamy appointed Interim Chief Executive Officer and Chief Scientific Officer.
- John Simard's 2025 total compensation was $30,134,204, including $17,341,326 severance.
- Dr. Sushma Shivaswamy's 2025 total compensation was $570,992.
- Angela Hu's 2025 total compensation was $245,419.
- Board of Directors consists of five members with established Audit, Compensation, and Nominating & Corporate Governance Committees.
- Craig Rademaker qualified as an audit committee financial expert.
- Compensation Committee delegated authority to the Interim CEO for certain option grants.